Mainz BioMed N.V., corporate

Mainz BioMed N.V.,

22.11.2022 - 14:03:09

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald?s Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

BERKELEY, US ? MAINZ, Germany ? November 22, 2022?? Mainz Biomed NV (NASDAQ:MYNZ) (?Mainz Biomed? or the ?Company?), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable conferences in November and December 2022, Deutsches Eigenkapitalforum 2022?and Cantor Fitzgerald?s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference.

Deutsches Eigenkapitalforum 2022? Date: November 28-30, 2022Location: Frankfurt, GermanyPresentation:?9:30 a.m. CET, Tuesday, November 29, 2022 The Deutsche Eigenkapitalforum has become one of the most important capital market conferences on the topic of corporate finance in Europe.

To register for the event, please visit http://www.eigenkapitalforum.com/#/en/76

Cantor Fitzgerald?s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference Date: December 8, 2022Location: Miami, FloridaPresentation: 10 a.m. EST, Thursday, December 8, 2022 Cantor Fitzgerald?s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference will feature one-on-ones with leading companies in the Medical & Aesthetic Dermatology, Ophthalmology & MedTech industries, as well as key opinion leaders in the dermatology and ophthalmology space.

To register for the event, please visit https://www.cantor.com/cantor-medical-aesthetic-dermatology-ophthalmology-conference/

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company?s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe and the United Arab Emirates with the intention of beginning its pivotal FDA clinical study in 2022 for US regulatory approval. Mainz Biomed?s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries -

In Europe: MC Services AG Anne Hennecke/Caroline Bergmann +49 211 529252 20mainzbiomed@mc-services.eu

In the US: Spectrum Science Melissa Laverty/Valerie Enes +1 540 272 6465mainz@spectrumscience.com

For investor inquiries, please contact?info@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are ?forward-looking statements? within the meaning of the ?safe harbor? provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as ?anticipate?, ?believe?, ?expect?, ?estimate?, ?plan?, ?outlook?, and ?project? and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company?s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the ?SEC?) by the Company. Additional information concerning these and other factors that may impact the Company?s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Company?s SEC filings are available publicly on the SEC?s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Issuer: Mainz BioMed N.V. Key word(s): Enterprise

Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Mainz BioMed N.V. Robert-Koch-Strasse 50 55129 Mainz

Germany Internet: mainzbiomed.com EQS News ID: 1492579 ? End of News EQS Media

@ dgap.de